Exelixis, Inc. (Nasdaq: EXEL) announced that its partner Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) has initiated a phase 3 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Management Comments

UPDATE: Exelixis (EXEL) Falls to Session Low on Cabozantinib and Opdivo DataSeptember 28, 2016 11:46 AM Exelixis Announces Collaborator Daiichi Sankyo’s Initiation of Phase 3 Clinical Development for CS-3150, a Selective Mineralocorticoid Receptor AntagonistSeptember 26, 2016 6:00 AM